Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
Nidhi Tandon, Vijay Ramakrishnan, Shaji K Kumar Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: The incorporation of various novel therapies has resulted in a significant survival benefit in newly diagnosed and relapsed patients with multiple myeloma (MM) over the past decade. Des...
Enregistré dans:
Auteurs principaux: | Tandon N, Ramakrishnan V, Kumar SK |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/26d3b8dbfff24a37b6b8c41b820ae08f |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
par: Joseph NS, et autres
Publié: (2021) -
The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
par: Al-Keilani MS, et autres
Publié: (2018) -
Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
par: Bingyi Zhou, et autres
Publié: (2021) -
GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment
par: Han-Gyu Chang, et autres
Publié: (2021) -
A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
par: Hao Wang, et autres
Publié: (2021)